

CURRICULUM VITAE



Amir Ghaemi; Ph.D.

Date of birth: January 27, 1980

Current Positions:

- Professor, Pasteur Institute of Iran, Tehran, Iran
-

Address: Institute Pasteur of Iran, Tehran, Iran

ghaem_amir@yahoo.com

A_ghaemi@pasteur.ac.ir

Educations:

Ph.D. in Medical virology (2005-2009)

Tarbiat Modares university (TMU), Tehran, Iran

M.Sc. in Medical Virology (2002-2005)

Tarbiat Modares University (TMU), Tehran, Iran.

GPA: 18.89/20.00

B.Sc. in Microbiology (1998-2002)

GPA: 16.46/20

Executive experiences:

1. Director of biotechnology committee, Novel industrial Centre, 2010-2011
2. Advisor of biotechnology committee, Novel industrial Center, 2011-2012

3. Manager of Biotechnology department, Golestan university of medical sciences, 2010-2012
4. Member of research committee of infectious disease research Centre, Golestan university of medical sciences, 2010-2012
5. Member of research committee of Golestan university of medical sciences, 2012-2013
6. Secretary of Iranian Society for Virology; 2019-2023
7. Director of influenza molecular diagnosis and serology laboratory, Pasteur institute of iran, 2018-2020
8. Director of influenza diagnosis and epidemiology laboratory, Pasteur institute of iran, 2020-2023

PROFESSIONAL EXPERIENCE

✓ 2020- 2022 Senior Researcher of recombinant vaccine design for SARS-Co2 virus; Pasteur Institute of Iran

2018- 2022 Senior Researcher of DNA vaccine design for influenza virus; Pasteur Institute of Iran
Supervisor of four PhD students and two M.S. students

2015- 2022 Senior Researcher; Oncolytic Viruses and Their Application to Cancer Treatment
Supervisor of three PhD students and three M.S. students

2010-2015 Golestan university of medical sciences, Design and development of cancer vaccines against human papillomavirus type.

Supervisor of four graduate students (M.S. students) and two PhD students

2005-2010 Ph.D. project, Thesis title: Design and construction of nanoparticle Lambda-phages for delivery of HPV- 16 E7 gene to animal cells and their immunological evaluation in tumor mice model

2005-2007 Study of gene therapy on latency and neurovirulence of Herpes Simplex Virus-1.

2002-2005 MS. project, Thesis title: Evaluation of Herpes Simplex Virus-1 latency in vaccinated mice after inoculation of DNA vaccine encoding gD-1 of HSV-1

Research Interests:

✓ Influenza Vaccines

- ✓ SARS-Co2 Vaccine
- ✓ Viral vaccine design
- ✓ Cancer Gene therapy
- ✓ Oncolytic therapy

Honors:

- ❖ Selected among the World's Top 2% Scientists, 2025, Ranked by Stanford University and Elsevier in the global database of leading scientists.
- ❖ Ranked 1st among 480 examinees for the M.Sc. entrance exam, held by the Iranian ministry of science, research and technology. (2002)
- ❖ PhD Scholarship from ministry of health and medical education (2005)
- ❖ Iran National Elite foundation member. (2008)
- ❖ Outstanding national Student Award of Iran (National). (2009)
- ❖ The best researcher of Golestan province. (2010)
- ❖ Young Assistant Professor Grant from Iran National Elite foundation. (2010)
- ❖ The Best researcher of Golestan University of medical sciences (2010, 2011, 2013, 2015)

Approved Grants:

1. Design and construction of nanoparticle Lambda-phages for delivery of HPV-16 E7 gene to animal cells and their evaluation as a booster-therapeutic vaccine in tumoric mice model. Iran food and drug organization. **Approval:** Golestan university of Medical sciences, **Position: Director, 2008.**
2. Design and construction of Lambda phage based- intelligent nanobioparticles as therapeutic vaccine against hepatitis C cancers. **Approval:** Golestan university of Medical sciences, **Position: Director,** Golestan university of Medical sciences. **2009.**
3. Design and development of stem cell secreting immunosuppressive cytokines as a novel therapeutic approach against multiple sclerosis. **Approval:** Tehran university of Medical sciences, **Position: Co-Director, 2010.**
4. Design and production of chitosan nanoparticles as HPV-16 E7 gene carriers in cervical cancer tumor mice model, **Approval:** Golestan university of Medical sciences, **Position: Director, 2012**
5. Immunologic evaluation of DNA vaccine encoding influenza virus M2 gene (prime) and purified M2 protein (Booster) in type A-influenza mice model, **Approval:** Golestan university of Medical sciences, **Position: Director, 2013**

6. Design and administration of DNA vaccine- peptide of HPV-16 E7 antigen in prime- boost strategy and evaluation of its antitumor efficacy, **Approval:** Golestan university of Medical sciences, **Position: Director, 2013**

7. Assessment of DNA vaccine encoding human papillomavirus type 16 E7 gene adjuvanted with TLR 3,4,9 agonists for induction of antitumor responses. **Approval:** Golestan university of Medical sciences, **Position: Director, 2013**

8. Antitumoral response assessment of Gemcitabine chemotherapy-DNA vaccine encoding HPV-16 E7 in papillomavirus type 16-associated tumor, **Approval:** Golestan university of Medical sciences, **Position: Director, 2014**

9. Evaluation of DNA vaccine encoding HPV-16 E7- melatonin adjuvant in immune response induction in Human papillomavirus-associated tumor animal models. **Approval:** Golestan university of Medical sciences, **Position: Director, 2014**

10. Comparing the efficacy of Influenza virosomes with chimeric Influenza-VSV virosomes for delivery of DNA vaccine in tumor mice model. **Approval:** Institute Pasteur of Iran **Position: Director, 2015**

11. Application of oncolytic Newcastle disease virus (NDV) in combination with influenza hemagglutinin Fusogenic membrane glycoproteins (FMGs) gene as novel therapy for murine model of human papillomavirus –induced cancer. **Approval:** Iran National Science Foundation (INSF), **Position: Director, 2017**

12. Evaluation of influenza virosome potency as carrier of plasmid expressing influenza genes and GM-CSF as genetic adjuvant **Approval:** Pasteur Institute of Iran **Position: Director, 2017**

13. Evaluation of immune response of virosome containing Synthetic Long peptide (SLP) of influenza virus using homologous prime-boost and heterologous (with gamma-inactivated influenza virus) in murine model. **Approval:** Pasteur Institute of Iran **Position: Director, 2017**

14. Recombinant vaccine design for SARS-Co2 virus, **Approval:** Iranian Biotechnology Development Council, **Position: Director, 2020**

15. Oncolytic Newcastle virotherapy against cervical cancer, **Approval:** Pasteur Institute of Iran **Position: Director, 2018**

16. Cells-Based Carrier for oncolytic newcastle disease virus in human papillomavirus associated tumor mice model **Approval:** Pasteur Institute of Iran , Iran university of Medical sciences **Position: Director, 2018**

17. Virotherapy effect of RSV **Approval:** Tehran university of Medical sciences **Position: Director, 2021**

Verified Peer- reviews (Publons) 144 review (ISI journals):

1. Journal for ImmunoTherapy of Cancer 17 times
2. International Immunopharmacology 10 times
3. Scientific Reports-8 times
4. Journal of Experimental & Clinical Cancer Research 8 times
5. Cancer Immunology, Immunotherapy-4 times
6. Life Sciences- 3 times
7. Expert Opinion on Biological Therapy- 2 times
8. Cancer Gene Therapy- 2 times
9. Human Gene Therapy-2 times
10. Frontiers in immunology 2 times
11. Nature Biotechnology

Invited Speaker

Pasteur Network Asia-Pacific Avian Influenza Symposium

December 10–11, 2024, Institut Pasteur du Cambodge, Phnom Penh, Cambodia

Presentation Title: "Flexible Strategies for Managing Avian Influenza in Diverse Ecosystems"

<https://pasteur-network.org/news/united-front-against-avian-influenza-insights-and-strategies-from-the-pasteur-network-asia-pacific-symposium>

Scientific Secretary of National Symposium on *Avian Influenza*

September 2025

Presentation Title: From Panzootic to Pandemic: Challenges of Highly Pathogenic Avian Influenza (H5N1) in Iran and Worldwide

ISI selected Publications:

Scopus h-index:29; Citations: 2920 (by Sep. 1, 2025)

Google scholar: h-index:35; Citations: 4160

1. Ghaemi, A(**Correspond Author**). and Ebrahimi, N., 2025. Analysis of H5N1 2.3. 4.4 b sublineage origins and K193 and N193 prevalence in human isolates. The Lancet Microbe. article no: 101112
2. Ghaemi, A(**Correspond Author**)., Ebrahimi, N. and Sadeh, S., 2025. Revisiting H7N9 Case Fatality Rate and Pathogenicity of Non-H5/H7 Avian Influenza Viruses. Reviews in medical virology, 35(4), p.e70045.
3. Zargarani, H., Ghaemi, A(**Correspond Author**)., Shenagari, M. and Samadi, M., 2025. Boosting immune response against cervical cancer: A combined approach using oncolytic virus and targeted therapies. PLoS One, 20(5), p.e0312979.
4. Ebrahimi, N., Sadeh, S. and Ghaemi, A(**Correspond Author**)., 2025. Is HA0-Mediated Heat Resistance in Influenza a Food Safety Concern? A Methodological Critique. Virology, p.110643.

5. Ghaemi, A., 2024. Viral concentrations in unpasteurised milk from avian influenza-infected cattle. *The Lancet Microbe*. 2024, article no: 101009
1. Ghaemi, A., 2024. Clarification on Rigvir's mechanism: Misinterpretation of CD55 inhibition in oncolytic therapy. *Virology*, p.110278.
2. Samadi, M., Mokhtari-Azad, T., Nejati, A., Norooz-Babaei, Z., Foroushani, A.R., Haghshenas, M.R., Adjaminejad, F., Zargar, H., Salimi, V. and Ghaemi, A(**Correspond Author**), 2023. The antitumor effect of oncolytic respiratory syncytial virus via the tumor necrosis factor- α induction and ROS-bax-mediated mechanisms. *BMC cancer*, 23(1), pp.1-12.
3. Shoraka S, Hosseini SM, Hasibi A, Ghaemi A, Mohebbi SR. The role of hepatitis B virus genome variations in HBV-related HCC: effects on host signaling pathways. *Frontiers in Microbiology*. 2023;14:1213145.
4. Saeedirad Z, Ariyanfar S, Noormohammadi M, Ghorbani Z, Naser Moghadasi A, Shahemi S, Ghanaatgar M, Rezaeimanesh N, Hekmatdoost A, Ghaemi A, Razeghi Jahromi S. Higher Dietary Acid Load Might Be a Potent Derivative Factor for Multiple Sclerosis: The Results from a Case–Control Study. *Nutrients*. 2023 Jul 26;15(15):3311.
5. Babazadeh SM, Zolfaghari MR, Zargar M, Baesi K, Hosseini SY, Ghaemi A(**Correspond Author**). Interleukin-24-mediated antitumor effects against human glioblastoma via upregulation of P38 MAPK and endogenous TRAIL-induced apoptosis and LC3-II activation-dependent autophagy. *BMC cancer*. 2023 Dec;23(1):1-3.
6. Ghaemi A, P Roshani, Zargar H, Hashimi A, Abdolalipour E, Miri M, Recombinant COVID-19 vaccine based on recombinant RBD/Nucleoprotein and saponin adjuvant induces long-lasting neutralizing antibodies and cellular immunity, *Front immunol* 2023, 13, 5127.
7. Miri SM, Pourhossein B, Hosseini SY, Keshavarz M, Shahmahmoodi S, Zolfaghari MR, Mohebbi SR, Gorji A, Ghaemi A(**Correspond Author**).. Enhanced synergistic antitumor effect of a DNA vaccine with anticancer cytokine, MDA-7/IL-24, and immune checkpoint blockade. *Virol J*. 2022 Jun 25;19(1)
8. Keshavarz M, Mohammad Miri S, Behboudi E, Arjeini Y, Dianat-Moghadam H, **Ghaemi A (Correspond Author)**.. Oncolytic virus delivery modulated immune responses toward cancer therapy: Challenges and perspectives. *Int Immunopharmacol*. 2022 Jul;108:108882.
9. Abdolalipour E, Mahooti M, Gorji A, Ghaemi A (**Correspond Author**). Synergistic Therapeutic Effects of Probiotic *Lactobacillus casei* TD-2 Consumption on GM-CSF-Induced Immune Responses in a Murine Model of Cervical Cancer. *Nutrition and Cancer*. 2022 Dec 26:1-11.
10. Sabbaghi, A., Malek, M., Abdolahi, S., Miri, S.M., Alizadeh, L., Samadi, M., Mohebbi, S.R., **Ghaemi, A (Correspond Author)**. A formulated poly (I:C)/CCL21 as an effective mucosal adjuvant for gamma-irradiated influenza vaccine *Virology Journal*, 2021: 18 (1), art. no. 201,
11. Samiee, F., Mohammadi, R., Shirian, S., Alijani, M.-R., Aledavood, A., Negahban, S., **Ghaemi, A (Correspond Author)**, Daneshbod, K., Daneshbod, Y. Spectrum of lymphoma subtypes based on the latest World Health Organization classification in southern Iran from 2000 to 2011 *Future Oncology*, 2021:17 (34), pp. 4733-4744.

12. Koushki, K., Salemi, M., Miri, S.M., Arjeini, Y., Keshavarz, M., **Ghaemi, A (Correspond Author)**. Role of myeloid-derived suppressor cells in viral respiratory infections; Hints for discovering therapeutic targets for COVID-19 *Biomedicine and Pharmacotherapy*, 2021: 144, art. no. 112346,
13. Rostaminia, S., Aghaei, S.S., Farahmand, B., Nazari, R., **Ghaemi, A (Correspond Author)**. Computational Design and Analysis of a Multi-epitope Against Influenza A virus *International Journal of Peptide Research and Therapeutics*, 2021: 27 (4), pp. 2625-2638.
14. Tanhaei, M., Mohebbi, S.R., Hosseini, S.M., Rafieepoor, M., Kazemian, S., Ghaemi, A., Shamloei, S., Mirjalali, H., Asadzadeh Aghdaei, H., Zali, M.R. The first detection of SARS-CoV-2 RNA in the wastewater of Tehran, Iran *Environmental Science and Pollution Research*, 2021: 28 (29), pp. 38629-38636.
15. Keshavarz, M., Sabbaghi, A., Koushki, K., Miri, S.M., Sarshari, B., Vahdat, K., **Ghaemi, A (Correspond Author)**. Epigenetic reprogramming mechanisms of immunity during influenza A virus infection *Microbes and Infection*, 2021, 23 (8), art. no. 104831,
16. Mozaffari Nejad, A.S., Noor, T., Munim, Z.H., Alikhani, M.Y., **Ghaemi, A (Correspond Author)**. A bibliometric review of oncolytic virus research as a novel approach for cancer therapy. *Virology Journal*, 2021, 18 (1), art. no. 98.
17. Farahtaj, F., Gholami, A., Khosravy, M.S., Gharibzadeh, S., Niknam, H.M., **Ghaemi, A (Correspond Author)**. Enhancement of immune responses by co-stimulation of TLR3 - TLR7 agonists as a potential therapeutics against rabies in mouse model. *Microbial Pathogenesis*, 2021,157, art. no. 104971
18. Farahtaj, F., Alizadeh, L., Gholami, A., Khosravy, M.S., Bashar, R., Gharibzadeh, S., Niknam, H.M., **Ghaemi, A(Correspond Author)**. Differential pathogenesis of intracerebral and intramuscular inoculation of street rabies virus and CVS-11 strains in a mouse model. *Iranian Journal of Basic Medical Sciences*, 2021,24 (7), pp. 943-950.
19. Shoraka, S., Ferreira, M.L.B., Mohebbi, S.R., **Ghaemi, A.** SARS-CoV-2 Infection and Guillain-Barré Syndrome: A Review on Potential Pathogenic Mechanisms. *Frontiers in Immunology* 2021, 12, art. no. 674922, **IF:7.51**
20. Sabbaghi A, Zargar M, Zolfaghari MR, Motamedi-Sedeh F, Ghaemi A **(Correspond Author)**. Protective cellular and mucosal immune responses following nasal administration of a whole gamma-irradiated influenza A (subtype H1N1) vaccine adjuvanted with interleukin-28B in a mouse model. *Archives Virology*. 2021 Jan 6:1–13
21. Sabbaghi A, Miri SM, Keshavarz M, Mahooti M, Zebardast A, Ghaemi A **(Correspond Author)** . Role of $\gamma\delta$ T cells in controlling viral infections with a focus on influenza virus: implications for designing novel therapeutic approaches. *Virol J*. 2020 Nov 12;17(1):174
22. Mir SM, Cho W, Tafsiri E, Ghaemi A**(Correspond Author)**. CRISPR-Cas, a robust gene-editing technology in the era of modern cancer immunotherapy, *Cancer Cell International*, 2020, 20(1), 456.
23. Mahooti M, Miri SM, Abdolalipour E, Ghaemi A**(Correspond Author)**. The immunomodulatory effects of probiotics on respiratory viral infections: A hint for COVID-19 treatment? *Microbial Pathogenesis*. 2020 Aug 18;148:104452.

24. Miri SM, Ebrahimzadeh MS, Abdolalipour E, Yazdi M, Hosseini Ravandi H, Ghaemi A **(Correspond Author)**. Synergy between hemagglutinin 2 (HA2) subunit of influenza fusogenic membrane glycoprotein and oncolytic Newcastle disease virus suppressed tumor growth and further enhanced by Immune checkpoint PD-1 blockade. *Cancer Cell International*. 2020 Aug 7;20:380. \
25. Mozaffari Nejad AS, Fotouhi F, Mehrbod P, Keshavarz M, Alikhani MY, Ghaemi A **(Correspond Author)**. Oncolytic effects of Hitchner B1 strain of newcastle disease virus against cervical cancer cell proliferation is mediated by the increased expression of cytochrome C, autophagy and apoptotic pathways. *Microbial Pathogenesis*. 2020 Aug 7;147:104438. ,
26. Higher prevalence of asymptomatic or mild COVID-19 in children, claims and clues. Miri SM, Noorbakhsh F, Mohebbi SR, **Ghaemi A (Correspond Author)**. *J Medical Virology*. 2020 May 29;10.1002/jmv.26069. doi: 10.1002/jmv.26069.
27. Virotheranostics, a double-barreled viral gun pointed toward cancer; ready to shoot. Keshavarz M, Sabbaghi A, Miri SM, Rezaeyan A, Arjeini Y, **Ghaemi A (Correspond Author)** *Cancer Cell International*, 2020, 20,1:1-17.
28. Oncolytic Newcastle disease virus delivered by Mesenchymal stem cells-engineered system enhances the therapeutic effects altering tumor microenvironment, Keshavarz M, Ebrahimzadeh S, Miri M, Dianat-Moghadam H, Ghorbanhosseini S, Mohebbi SR, Keyvani H, **Ghaemi A (Correspond Author)**. *Virology Journal*, 2020, 17:64.
29. Evaluation of the antitumor immune responses of probiotic *Bifidobacterium bifidum* in human papillomavirus-induced tumor model. Abdolalipour, E., Mahooti, M., Salehzadeh, A., Torabi, A., Mohebbi, S.R., Gorji, A., Ghaemi A (Correspond Author). *Microbial Pathogenesis*, 2020, 145,104207,
30. Association of Interleukin-17 gene polymorphisms with susceptibility to chronic hepatitis B virus infection and clearance in Iranian population. Tayefinasrabadi, H., Mohebbi, S.R., Hosseini, S.M., Azimzadeh, P., Pourhoseingholi, M.A., **Ghaemi, A.**, Sharifian, A., Asadzadeh Aghdaei, H., Zali, M.R. *Microbial Pathogenesis*, 2020 144,104195,
31. Gut-brain Axis and migraine headache: A comprehensive review. Arzani, M., Jahromi, S.R.,hiria Ghorbani, Z., Vahabizad, F., Martelletti, P., **Ghaemi, A.**, Sacco, S., Togha, M. *Journal of Headache and Pain*, 2020, 21 (1),15.
32. Evaluation of Inflammatory State in Migraineurs: A Case-control Study. Togha M, Razeghi Jahromi S, Ghorbani Z, Ghaemi A, Rafiee P. *Iran J Allergy Asthma Immunol*. 2020 May 17;19(S1):83-90. .
33. Oncolytic Newcastle disease virus reduces growth of cervical cancer cell by inducing apoptosis. Keshavarz, M., Nejad, A.S.M., Esghaei, M., Bokharaei-Salim, F., Dianat-Moghadam, H., Keyvani, H., **Ghaemi A (Correspond Author)**. *Saudi Journal of Biological Sciences*, 2020, 27 (1), pp. 47-52.
34. An investigation of oxidant/antioxidant balance in patients with migraine: A case-control study. Togha, M., Razeghi Jahromi, S., Ghorbani, Z., **Ghaemi, A.**, Rafiee, P. *BMC Neurology*, 2019, 19 (1), 323.
35. Inactivation methods for whole influenza vaccine production. Sabbaghi A, Miri SM, Keshavarz M, Zargar M, **Ghaemi A (Correspond Author)**. *Rev Med Virol*. 2019 Jul 23:e2074. doi: 10.1002/rmv.2074.

36. Oncolytic paramyxoviruses-induced autophagy; a prudent weapon for cancer therapy. Keshavarz M, Solaymani-Mohammadi F, Miri SM, **Ghaemi A (Correspond Author)**. J Biomed Sci. 2019 Jun 19;26(1):48. doi: 10.1186/s12929-019-0542-9. Review.
37. Human rotavirus in Iran; molecular epidemiology, genetic diversity and recent updates on vaccine advances Tavakoli Nick S, Mohebbi SR, Ghaemi A, Hosseini SM Gastroenterol Hepatol Bed Bench. 2019 Spring;12(2):98-109. Review.
38. Immunomodulatory and prophylactic effects of Bifidobacterium bifidum probiotic strain on influenza infection in mice. Mahooti M, Abdolalipour E, Salehzadeh A, Mohebbi SR, Gorji A, **Ghaemi A (Correspond Author)**. World J Microbiol Biotechnol. 2019 Jun 3;35(6):91. doi: 10.1007/s11274-019-2667-0.
39. A gene variation of Interferon Gamma Receptor-I promoter (rs1327474A>G) and chronic hepatitis C virus infection. Karkhane M, Mohebbi SR, Sharifian A, Ghaemi A, Asadzadeh Aghdaei H, Zali MR Gastroenterol Hepatol Bed Bench. 2019 Winter;12(1):46-51.
40. Non-replicating Newcastle Disease Virus as an adjuvant for DNA vaccine enhances antitumor efficacy through the induction of TRAIL and granzyme B expression. Mohebbi A, Ebrahimzadeh MS, Baghban Rahimi S, Saeidi M, Tabarraei A, Mohebbi SR, Shirian S, Gorji A, **Ghaemi A (Correspond Author)**. Virus Res. 2019 Feb;261:72-80.
41. Natural Infection with Rabies Virus: A Histopathological and Immunohistochemical Study of Human Brains. Farahtaj F, Alizadeh L, Gholami A, Tahamtan A, Shirian S, Fazeli M, Nejad ASM, Gorji A, Niknam HM, **Ghaemi A (Correspond Author)**. Osong Public Health Res Perspect. 2019 Feb;10(1):6-11.
42. Vaccination with three tandem repeats of M2 extracellular domain fused to Leishmania major HSP70 protects mice against influenza A virus challenge. Shokouhi H, Farahmand B, **Ghaemi A**, Mazaheri V, Fotouhi F. Virus Res. 2018 Jun 2;251:40-46.
43. Antitumor Immunity Induced by Genetic Immunization with Chitosan Nanoparticle Formulated Adjuvanted for HPV-16 E7 DNA Vaccine. Tahamtan A, Barati M, Tabarraei A, Mohebbi SR, Shirian S, Gorji A, **Ghaemi A (Correspond Author)**. Iran J Immunol. 2018 Dec;15(4):269-280.
44. Enhancement of therapeutic DNA vaccine potency by melatonin through inhibiting VEGF expression and induction of antitumor immunity mediated by CD8⁺ T cells. Baghban Rahimi S, Mohebbi A, Vakilzadeh G, Biglari P, Razeghi Jahromi S, Mohebi SR, Shirian S, Gorji A, **Ghaemi A (Correspond Author)**. Arch Virol. 2018 Mar;163(3):587-597.
45. Adjuvant use of the NKT cell agonist alpha-galactosylceramide leads to enhancement of M2-based DNA vaccine immunogenicity and protective immunity against influenza A virus. Fotouhi F, Shaffifar M, Farahmand B, Shirian S, Saeidi M, Tabarraei A, Gorji A, **Ghaemi A (Correspond Author)**. Archive of Virol. 2017; 162:1251–1260
46. Synergistic effect of programmed cell death protein 1 blockade and secondary lymphoid tissue chemokine in the induction of anti-tumor immunity by a therapeutic cancer vaccine, Moeini S, Saeidi M, Fotouhi F, Mondanizadeh M, Shirian S, Mohebi A, Gorji A, **Ghaemi A (Correspond Author)**. Archive of Virol. 2017; 162:333-346
47. Astrocyte-mediated inflammation in cortical spreading depression. Ghaemi A (First Author), Alizadeh L, Babaei S, Jafarian M, Khaleghi Ghadiri M, Meuth SG, Kovac S, Gorji A. Cephalalgia. 2017 Jan 1:0333102417702132.

48. Spectrum of pediatric tumors diagnosed by fine-needle aspiration cytology. *Medicine (Baltimore)*. Shirian S, Daneshbod Y, Haghpanah S, Khademi B, Noorbakhsh F, **Ghaemi A**, Mosayebi Z. 2017 Feb;96(6):e5480.
49. Rapamycin Augments Immunomodulatory Properties of Bone Marrow-Derived Mesenchymal Stem Cells in experimental autoimmune encephalomyelitis, toghae M, Jahanshahi M, Alizadeh L, Razeghi S, Gorji A and **Ghaemi A (Correspond Author)**, *Mol Neurobiol* 2016 10.1007/s12035-016-9840-3
50. Combination of the Toll like receptor agonists and α -Galactosylceramide as an Efficient Adjuvant for Cancer Vaccine, Gableh F, Saeedi M, Hamdi K, Gorji A, **Ghaemi A (Correspond Author)**, *Journal of biomedical science*, 2015 25(23)1:16-
51. Chitosan Nanoparticles as a potential non-viral gene delivery for HPV-16 E7 into mammalian cells, Tahamtan A, Tabarraei A, Moradi A, Dinarvand M, Kelishadi M, , Fatemeh Atyabi F, **Ghaemi A (Correspond Author)**, *Artificial Cells, Nanomedicine and Biotechnology* 2015, 43: 366–372.
52. The Effect of Melatonin on Behavioral, Molecular, and Histopathological Changes in Cuprizone Model of Demyelination. Vakilzadeh G, Khodaghohi F, Ghadiri T, **Ghaemi A**, Noorbakhsh F, Sharifzadeh M, Gorji A, *Mol Neurobiol*. 2015 Aug 27
53. Immunomodulatory Effect of Toll-Like Receptor-3 Ligand Poly I:C on Cortical Spreading Depression. **Ghaemi A**, Sajadian A, Khodaie B, Lotfinia A, Lotfinia M, Aghabarari F, Khaleghi Ghadiri M, Meuth A, Gorji A. *Mol Neurobiol* 2015 DOI 10.1007/s12035-014-8995-z.
54. Antitumor effect of therapeutic HPV DNA vaccines with Chitosan-Based Nanodelivery Systems, Tahamtan A, **Ghaemi A (Correspond Author)**, Gorji A, Kalhor HR, Sajadian A, Tabarraei A, Moradi A, Atyabi F, Kelishadi M, *Journal of biomedical science*, 2014 31;21:69.
55. DNA vaccine encoding HPV-16 E7 with mutation in L-Y-C-Y-E pRb-binding motif induces potent anti-tumor responses in mice, Alagheband Bahrami A, **Ghaemi A (Correspond Author)**, Tabarraei A, Sajadian A, Gorji A, Soleimanjahi H. *Journal of Virological Methods* 2014 206 (2014) 12–18
56. Enhanced Cell Immune Responses to Hepatitis C Virus Core by Novel Heterologous DNA Prime/Lambda Nanoparticles Boost in Mice, Saeedi A , **Ghaemi A (Correspond Author)**, Tabarraei A, Moradi A , Gorji A, Semnani S, Soleimanjahi H, Hosseinzadeh Adli A, Hosseini SY, Vakili MA, *Virus Genes*, 2014,49(1):11-21.
57. Comparing the effect of Toll-Like Receptor Agonist adjuvants on the efficiency of the DNA vaccine, Sajadian A, Tabarraei A, Soleimanjahi H, Moradi A, Fotouhi F, Gorji A, **Ghaemi A (Correspond Author)**, *Archive of virology*, 2014, 159(8):1951-1960.
58. Chitosan Nanoparticles as a potential non-viral gene delivery for HPV-16 E7 into mammalian cells, Tahamtan A, Tabarraei A, Moradi A, Dinarvand M, Kelishadi M, Atyabi F, **Ghaemi A (Correspond Author)**, *Artificial Cells, Nanomedicine and Biotechnology* 2014 DOI: 10.3109/21691401.2014.893522.
59. Immunogenicity evaluation of a DNA vaccine expressing the Hepatitis C Virus NS2 gene in C57BL/6 mice, Gorzin Z, Gorzin A, Tabarraei A, Behnampour N, Irani S, Gorji A, **Ghaemi A (Correspond Author)**, *Iranian Biomedical journal*, 2014,18(1):1-7.

60. Protective Effect of a cAMP Analogue on Behavioral Deficits and Neuropathological Changes in Cuprizone Model of Demyelination, Vakilzadeh G, Khodaghohi F, Ghadiri T, Darvishi M, **Ghaemi A**, Noorbakhsh F, Gorji A, Sharifzadeh M, Molecular Neurobiology, 2015, 52(1):130-141.
61. Alleviation of experimental allergic encephalomyelitis in C57BL/6 mice by soy daidzein, Razezagh S, Arefhosseini SR, **Ghaemi A**, Toghae M, Iranian Journal of Allergy, Asthma and Immunology, 2014, 13(4):256-264.
62. Interleukin-12 as a genetic adjuvant enhances hepatitis C virus NS3 DNA vaccine immunogenicity, Naderi M, Saeedi A, Kelishadi M, Moradi A, Gorji A, **Ghaemi A (Correspond Author)**, Virologica Sinica. 2013, 28(3): 167-173.
63. HSP70 modified response against HPV based tumor, Farzanehpour M, Soleimanjahi H, Hassan ZM, Amanzadeh A, **Ghaemi A**, Fazeli M, European Review for Medical and Pharmacological Sciences ERMPS, 2013, 17:228-234.
64. Genistein Induces a Protective Immunomodulatory Effect in a Mouse Model of Cervical Cancer, **Ghaemi A (Correspond Author)**, Soleimanjahi H, Razezghi S, Gorji A, Tabarraei A, Iranian Journal of immunology 2012; 9(2):119-127.
65. Lambda Phage nanoparticles for Targetomics, **Ghaemi A (Correspond Author)**, Tabarraei A, Soleimanjahi H, Gorji A, Biotechnology 2012; 11(2): 95-99.
66. Mutations in the S gene region of hepatitis B virus genotype D in Golestan Province-Iran. Moradi A, Zhand S, **Ghaemi A**, Javid N, Tabarraei A. Virus Genes. 2012; 44:382-387.
67. Tissue Inhibitors of Matrix Metalloproteinase-3, potential therapeutic target against Multiple sclerosis. **Ghaemi A (Correspond Author)**, Hamdi K, Togha M, Kazemi H, Gorji A, American Journal of Biochemistry and Molecular biology 2012; 2(3): 195-199.
68. Protection of mice by a Lambda-based therapeutic vaccine against HPV16-associated cancer. **Ghaemi A**, Soleimanjahi H, Gill P, Hassan Z, Razezghi S, Fazeli M, Razavinikoo MH, Intervirology 2011; 19; 54(3):105-112.
69. Efficacy of HPV-16 E7 Based Vaccine in a TC-1 Tumoric Animal Model of Cervical Cancer. Fazeli M, Soleimanjahi H, **Ghaemi A**, Farzanehpour M, Amanzade A, Hashemi R, Cell Journal 2011; 12(4): 483-488.
70. Recombinant Lambda-phage nanobioparticles for tumor therapy in mice models. **Ghaemi A**, Soleimanjahi H, Gill P, Hassan Z, Razezghi S, Roohvand F, Genetic Vaccine and Therapy 2010; 8(3):1-7.
71. Localization of Herpes Simplex Virus Type 1 DNA in Latently Infected BALB/c Mice Neurons Using in situ Polymerase Chain Reaction. Khansarinejad B, Soleimanjahi H, **Ghaemi A**, taki T, Iranian Biomedical Journal 2010; 14 (3): 83-88.
72. Echinacea purpurea Polysaccharide Reduces the Latency Rate in Herpes Simplex Virus Type-1 Infections. **Ghaemi A (Correspond Author)**, Soleimanjahi H, Gill P, Arefian E, Soudi S, And Hassan Z. Intervirology 2009; 52:29-34.
73. Virulence Increasing of Salmonella typhimurium in Balb/c Mice After Heat-Stress Induction of Phage Shock Protein A. Hassani AS, Amirmozafari N, **Ghaemi, A (Correspond Author)**, Current Microbiology. 2009; 59:446-450.

74. A Kinetic Study of Gamma Interferon Production in Herpes Simplex Virus–1 DNA Prime-Protein Boost Regimen Comparing to DNA or Subunit Vaccination. Arefian E, Bamdad T, Soleimanjahi H, Akhoond M, Parsania M, **Ghaemi A**. Cell Molecular Biology, 2009; 43 (3):388–393.
75. Phage shock protein G, a Novel Ethanol Induced Stress Protein in Salmonella typhimurium. Shoaehassani A, Malekzadeh F, Amirmozafari N, Hamdi K, Ordouzadeh N, **Ghaemi A. (Correspond Author)**. Current Microbiology. 2009; 58:239-244.
76. In vitro inhibition of Helicobacter pylori urease with non and semi fermented Camellia sinensis. Shoaehassani A, Ordouzadeh N, Hamdi K, **Ghaemi A. (Correspond Author)** Nazari R, Amirmozafari N. Indian Journal of Medical Microbiology. IJMM. 2009;27(1):30-34.
77. Nucleic Acid Isothermal Amplification Technologies - A Review, Gill P and **Ghaemi A**. Nucleoside, nucleotide and nucleic acid. NNNA. 2008; 27:224–243.
78. Nanodiagnostic Method for Colorimetric Detection of Mycobacterium tuberculosis 16S rRNA. Gill P, Ghalami M, **Ghaemi A**, Mosavari N, Abdul-Tehrani H, Sadeghizadeh M. Nanobiotechnology 2008; 4: 28-35.
79. Prophylactic effects of Echinacea purpurea polysaccharide against lethal ocular herpes simplex virus type I. **Ghaemi A**, Soleimanjahi H, Gill P, Arefian E, Soudi S, Hassan Z. Saudi S. Medical Journal. SMJ 2008; 29(8): 1203-1205.
80. Volatile components of Commellia sinensis inhibit growth and biofilm formation of oral Streptococci in vitro. Shoaehassani A, Amirmozafari N, Ordouzadeh N, Hamdi K, Nazari R, **Ghaemi A**. Pakistan Journal of Biological Sciences. PJBS 2008; 11(10): 1336-1341.
81. Induction of humoral and cellular immunity against latent HSV-1 infection by DNA immunization in BALB/c mice. **Ghaemi A**, Soleimanjahi H, Bamdad T, Arefian E. Comparative microbiology, immunology and infectious disease CIMID. 2007; 30: 197-210.
82. Molecular detection of Mycobacterium tuberculosis by tHDA-ELISA DIG detection system, Gill, P, Abdul-Tehrani, H, **Ghaemi A**, Hashempour T, VP Amiri, Ghalami M, Eshraghi N, Noori-Dalooi M. International Journal of Antimicrobial Agents. 2007; 29: 570-571.
83. Thermophilic helicase-dependent isothermal DNA amplification for molecular detection of Helicobacter pylori, Gill P, Abdul-Tehrani H, **Ghaemi A**, Hashempour T, Alvandi A, Noori-Dalooi M. International Journal of Antimicrobial Agents. 2007; 29: 135-136.
84. Evaluation of gamma interferon Kinetics in Herpes Simplex Virus infected mice in different days post infection (in vivo) and post re-stimulation (in vitro). Arefian A, Bamdad, T, Soleimanjahi H, Sabahi F, Akhoond R, Parsania M, **Ghaemi A**. Comparative Immunology, Microbiology & Infectious Diseases. CIMID. 2007; 30:1–9.
85. Detection of helicobacter pylori by enzyme-linked immunosorbent assay of thermophilic helicase-dependent isothermal DNA amplification, Gill P, Amini M, **Ghaemi A**, Shokouhizadeh L, Abdul-Tehrani H, Karami A, Gilag A. Diagnostic Microbiology and infectious Disease. DMID 2007; 59: 243-249.
86. Pro12Ala polymorphism of the PPARγ-2 gene is associated with insulin resistance and type 2 diabetes in an Iranian population. Meshkani R, Taghikhani M, Larijani B, Bahrami Y, Khatami S, Khoshbin E, **Ghaemi A**, Sadeghi S, Mirkhani F, Molapour A and Adeli K. Clinical Chemistry and Laboratory Medicine CCLM. 2007;45(4):477-482.

87. Antileishmanial effect of Echinacea purpurea root extract cultivated in Iran. Soudi S, Hashemi SM, Zavarani A, **Ghaemi A**, Jafarabadi M. Iranian Journal of Pharmaceutical Research. 2007;6(2):147-149.
88. Enzyme-linked immunosorbent assay of nucleic acid sequence-based amplification for molecular detection of M. tuberculosis, Gill P, Ramezani R, Amiri M, **Ghaemi A**, Hashempour T, Eshraghi N, Ghalami M, Tehrani H. Biochemical and Biophysical research communication. BBRC. 2006; 374:1151-1157.IF:2.29,
89. PCR detection of Thymidine Kinase gene of latent Herpes simplex virus type 1 in mice trigeminal ganglia. **Ghaemi A**, Soleimanjahi H, Bamdad T, Roostaei MH and Arefian E. Archives of Razi Institute. 2006; 61(3): 136-141.

Patents:

- Prophylactic effect of Echinacea purpurea extract on ocular disease caused by HSV-1. **A. Ghaemi** and H. Soleimanjahi, **Iranian patent office**.

Books:

Sabbaghi A, Ghaemi A. Molecular Adjuvants for DNA Vaccines: Application, Design, Preparation, and Formulation. **Springer Protocols book series , Methods in Molecular Biology**, DNA Vaccines, Methods and Protocols, . 2021;2197:87-112. PMID: 32827133. DOI: <https://doi.org/10.1007/978-1-0716-0872-2> (MIMB, volume 2197)

Probiotic based anticancer immunity in cervical cancer, Probiotics in anticancer immunity, Bentham books, 2023, Abdolalipour E, Mahooti M, Ghaemi A

Research Students, Supervisor:

1. 10 Student (M.Sc student of Azad University- Microbiology- Biotechnology) 2009-2018
2. 3 Student (M.Sc student of Golestan university of medical sciences- Biotechnology) 2011-2014
3. 7 Student (M.Sc student of Golestan university of medical sciences- Virology) 2011-2016
4. 4 Student (PhD student of Tehran university of medical sciences- Virology) 2015-2020

5. 6 Student (PhD student of Azad University - Microbiology) 2015-2020

Nucleotides in NCBI

1. Synthetic construct E7 protein (E7) gene, complete cds, GenBank: KC344538
2. Synthetic construct E7 protein (E7) gene, complete cds, GenBank: KC410871.1
3. Hepatitis B virus isolate GOR-1391 core protein gene, partial cds, GenBank: KC928094.1
4. Hepatitis B virus isolate GOR-1390-1 S protein (S) gene, partial cds, GenBank: KC633131.1